Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Contents · Professional Essentials

For professionals · Professional Essentials

Polymyalgia rheumatica and its mimics

The first assessment, the difficult taper and the visit that changes urgency.

A 72-year-old woman can no longer put on her coat without help. Both shoulders and the backs of her thighs ache on waking. By lunchtime she moves more freely.

Five months later, after regaining much of her independence on prednisone, she reports that dressing is difficult again. Ask her to show you how.

On one visit she might again be stiff across both shoulders. On another she might reach easily with the left arm and stop because of focal pain on the right. The same loss of function can call for two different decisions.

Establish what is inflamed

Ask when the change began and what the patient can do later in the day. New bilateral shoulder-girdle pain and prolonged morning stiffness after age 50 support PMR. Hip or buttock discomfort, difficulty turning in bed and the time needed to rise from a chair help define the extent of involvement.

A patient may call painful effort “weakness.” Compare active and passive movement, then test strength in a position the patient can tolerate. Record an everyday task to repeat at follow-up.

Examine the hands, wrists and knees as well as the shoulders and hips. Distal findings can occur in PMR. Symmetric small-joint synovitis that persists or becomes more prominent raises the probability of elderly-onset rheumatoid arthritis. Recurrent abrupt attacks with a knee or wrist effusion point toward crystal arthritis.

Aspirate a hot effusion when feasible and send fluid for culture and crystal analysis. A positive crystal examination still leaves open the possibility of a coexisting infection.

Obtain ESR, CRP, a blood count and a biochemical profile before glucocorticoids when clinically feasible. Direct further tests at the discrepancy you need to explain.

Objective weakness might prompt creatine kinase and thyroid testing. Anemia, focal skeletal pain and renal dysfunction warrant consideration of a plasma-cell disorder. Symptoms, examination and the time course determine how much weight to give each result.

Recognize the visit that cannot wait

Ask about new headache, scalp tenderness, jaw or tongue fatigue on chewing, transient visual obscuration and diplopia at the initial visit and again when symptoms change. A patient whose sight has returned can describe the event in the past tense and appear comfortable in the room.

Transient or persistent visual loss or new diplopia requires immediate assessment, including same-day ophthalmologic evaluation when GCA is suspected. At high clinical suspicion, start appropriate GCA treatment immediately while arranging confirmation. A patient can develop GCA while already taking a PMR dose of prednisone.

Giant cell arteritis can also present with arm claudication, discrepant pulses or blood pressures, persistent fever or weight loss. Cranial symptoms may be absent.

Choose the diagnostic route according to the vascular territory, local expertise and availability. Expert ultrasound of the temporal and axillary arteries is the EULAR first-line imaging strategy for suspected GCA. The American College of Rheumatology conditionally favors temporal artery biopsy in the US context. Where vision is threatened, the treatment decision precedes the test result.

Use imaging when the answer could change care

A typical case with a convincing examination may need no imaging to support a working diagnosis. The 2026 international PMR imaging recommendations identify intermediate clinical probability as the setting in which testing is especially informative. At that point, define what the study could resolve.

A shoulder ultrasound can show inflammation around both subacromial-subdeltoid bursae or biceps tendons. It can also identify a cuff abnormality that fits one focal complaint. Either finding still requires correlation with the rest of the examination.

When deep pelvic symptoms dominate or an alternative structural lesion is suspected, MRI can address anatomy beyond the reach of routine ultrasound. Selected patients with persistent constitutional symptoms or suspicion of large-vessel vasculitis may benefit from a broader imaging assessment.

Record glucocorticoid exposure when interpreting the study, since treatment can reduce inflammatory signals. Current evidence does not support vascular screening of every asymptomatic PMR patient or using serial scans to set the glucocorticoid dose.

Define a response the patient and clinician can recognize

In confirmed isolated PMR, choose a starting dose that takes disease burden and vulnerability to steroid toxicity into account. The current EULAR guidance gives 15–25 mg/day prednisone equivalent. BSR starts at 12.5–15 mg/day prednisolone and allows an increase to 25 mg if needed for symptom control.

Agree on what improvement should look like, when to review it and whom to contact if the pattern changes. An incomplete response calls for a new examination before further dose increases.

During taper, ask which original symptoms have returned, when they recurred and what dose the patient actually took. Isolated unilateral hip pain with weight bearing after months of treatment warrants assessment for fracture or osteonecrosis. Fatigue, nausea and postural symptoms at low doses can require evaluation for adrenal insufficiency.

Review fever or a focal infectious syndrome promptly. On IL-6 receptor blockade, a low CRP carries limited reassurance about active PMR, GCA or infection. Follow function and examination alongside the laboratory trend.

At each treatment decision, ask about the cost of continued glucocorticoids for this patient. Hyperglycemia, falls, prior fragility fractures and accumulated exposure can change the balance well before another relapse.

Assess fracture risk, discuss feasible activity and arrange bone protection where indicated. A patient who can now dress independently but is falling on the way to the bathroom has an important outcome to address.

Match steroid-sparing treatment to the population studied

For repeated inflammatory relapse or substantial glucocorticoid toxicity, reassess the diagnosis, then discuss a steroid-sparing strategy. Randomized evidence supports methotrexate in recently diagnosed PMR.

In SAPHYR, sarilumab improved sustained remission at one year in patients who relapsed during taper. The study compared different prednisone taper schedules across arms. The US PMR indication covers adults with an inadequate corticosteroid response or intolerance of the taper. Where tocilizumab is considered for isolated PMR, distinguish the trial evidence from its separate regulatory indication in GCA.

The professional research chapter follows therapies through trials and regulatory decisions. REPLENISH studied secukinumab in relapsing PMR with the same glucocorticoid taper across groups. The EU indication includes adults with inadequate glucocorticoid response or relapse during taper. In the United States, secukinumab is approved for adults with PMR when corticosteroids have not worked well enough or when the patient cannot tolerate a corticosteroid taper.

Differences in populations, taper schedules and endpoint definitions prevent direct efficacy rankings across PMR trials. Record the patient's goal for an additional drug, the safety monitoring it requires and the point at which you would reconsider it.

What to remember

At the next visit, compare the patient's present limitation with the one you documented before treatment. A change in distribution, strength, vascular symptoms or systemic illness may change the diagnosis and the urgency of care.

Sources

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Polymyalgia rheumatica